Fireside Chat with Mike Langford - Spire Pathology Network Lead

Mike Langford, as head of Pathology at Spire, is the key person for diagnostic testing for the c.800,000 patients it treats annually. While Spire has its own in-house pathology and diagnostics capability, it also works with the major outsourced providers like SourceBio International. With the NHS looking to work with the private sector to reduce all-time record waiting lists (10m expected patients by year end vs. 4m at end of 2019), Spire will be a key player in this process as the largest private hospital operator. This swell in demand will have a knock-on effect on pathology services and demand which is likely to benefit Source. In addition to this more traditional relationship, Spire is also working with Source as part of its COVID-19 testing programme - something which is key for Spire to return to normal elective procedures capacity.

This call should help to contextualise the significance of the record waiting list expansion on demand for private hospital and lab services whilst also helping investors to better understand the importance of PCR testing for COVID-19 with regard to hospital services resuming normal operations.

Click below to listen the full conference call. Please contact CIR@liberum.com for the password.

This communication is for use only by a person or entity that qualifies as a "Professional Client" or "Eligible Counterparty" within the meaning of the FCA's rules. It is intended for use only by persons having professional experience in matters relating to investments. Any other person who receives this should not act on the contents. Disclaimer here